IMPACT OF INDUCTION WITH BASILIXIMAB IN COMBINATION WITH TACROLIMUS-BASED IMMUNOSUPPRESSIVE REGIMEN IN LIVING DONOR LIVER TRANSPLANTATION.

被引：0
|
作者：
Aoyagi, Takeshi [1 ]
Taniguchi, Masahiko [1 ]
Furukawa, Hiroyuki
Shimamura, Tsuyoshi [1 ]
Suzuki, Tomomi
Yamashita, Kenichiro [1 ]
Todo, Satoru [1 ]
机构：
[1] Hokkaido Univ, Grad Sch Med, Dept Gen Surg, Sapporo, Hokkaido, Japan
来源：
LIVER TRANSPLANTATION | 2008年 / 14卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
下载
收藏
页码：S105 / S105
页数：1
相关论文
共 50 条
  • [41] THE OPTIMAL RITUXIMAB REGIMEN IN ADULT ABO-INCOMPATIBLE LIVING DONOR LIVER TRANSPLANTATION.
    Oike, Fumitaka
    Egawa, Hiroto
    Takada, Yasutugu
    Uemoto, Shinji
    LIVER TRANSPLANTATION, 2008, 14 (07) : S246 - S246
  • [42] Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation
    Salizzoni, M
    Cavallari, A
    Risaliti, A
    Filipponi, F
    Gerunda, GE
    Forti, D
    Fassati, LR
    Cillo, U
    Castagneto, M
    Valente, U
    Tisone, G
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (03) : 2258 - 2262
  • [43] DELAYED INTRODUCTION OF TACROLIMUS WITH BASILIXIMAB INDUCTION THERAPY IN CADEVERIC LIVER TRANSPLANTATION
    Fernandes, Mark L.
    Chang, Stephen K.
    Da Costa, Maureen
    Madhaven, Krishnakumar
    Prabhakaran, K.
    Lee, Kang H.
    Lim, Seng G.
    LIVER TRANSPLANTATION, 2008, 14 (07) : S111 - S111
  • [44] Basiliximab Is an Effective Immunosuppressive Agent Which Allows for Renal Protection in Liver Transplantation.
    Stokes, J.
    Ally, W.
    Flohr, T.
    Sawyer, R.
    Agarwal, A.
    Brayman, K.
    Schmitt, T.
    Kumer, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 265 - 265
  • [45] Impact of Sarcopenia on Survival in Patients Undergoing Living Donor Liver Transplantation.
    Kaido, Toshimi
    Ogawa, Kohei
    Fujimoto, Yasuhiro
    Ito, Takashi
    Tomiyama, Koji
    Mori, Akira
    Uemoto, Shinji
    LIVER TRANSPLANTATION, 2013, 19 : S97 - S97
  • [46] Impact of MHV inclusion in right lobe living donor liver transplantation.
    Kakodkar, R.
    Soin, A. S.
    Saigal, S.
    Nundy, S.
    LIVER TRANSPLANTATION, 2007, 13 (06) : S68 - S68
  • [47] DONOR CYP3A5 GENOTYPES AND GRWR IMPACT PHARMACOLOGICAL EFFECTS OF TACROLIMUS AFTER PEDIATRIC LIVING DONOR LIVER TRANSPLANTATION.
    Wan, P.
    Xue, F.
    Luo, Y.
    Feng, M.
    Qiu, B.
    Zhang, J.
    Xia, Q.
    PEDIATRIC TRANSPLANTATION, 2017, 21 : 35 - 35
  • [48] The use of alemtuzumab induction and tacrolimus monotherapy in liver transplantation.
    Eghtesad, B
    Marcos, A
    Fung, J
    Fontes, P
    Tom, K
    Devera, M
    Marsh, W
    Gayowski, T
    Shakil, O
    Demetris, A
    Murase, N
    Starzl, T
    HEPATOLOGY, 2004, 40 (04) : 552A - 552A
  • [49] Efficacy of Induction Therapy in Adult-to-Adult Living Donor Liver Transplantation.
    McGilvray, Ian
    Renner, Eberhard
    Lilly, Leslie
    Levy, Gary
    Grant, David
    Greig, Paul
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 693 - 694
  • [50] Excellent Short-Term Outcome of Reduced Dose of Mycophenolate Mofetil With Tacrolimus Combination Immunosuppression in Living Donor Liver Transplantation.
    Kim, Hyeyoung
    Yi, Nam-Joon
    Lee, Juyeun
    Park, Min-Su
    Choi, YoungRok
    Hong, Geun
    Lee, Hae Won
    Lee, Kwang-Woong
    Suh, Kyung-Suk
    LIVER TRANSPLANTATION, 2014, 20 : S321 - S321
12345